|
D5878
|
|
Digitoxin ≥92% (HPLC), powder
|
|
|
|
|
|
|
D6003
|
|
Digoxin analytical standard
|
A cardiac glycoside, substrate for Pgp, upregulates Pgp expression and down regulates SXR (Steroid Xenobiotic Receptor).
|
human ... ABCB1(5243), CYP3A4(1576) mouse ... Abcb1a(18671), Abcb1b(18669) rat ... Atp1a1(24211)
|
|
|
|
|
D6770
|
|
Digoxin analytical standard
|
A cardiac glycoside, substrate for Pgp, upregulates Pgp expression and down regulates SXR (Steroid Xenobiotic Receptor).
|
human ... ABCB1(5243), CYP3A4(1576) mouse ... Abcb1a(18671), Abcb1b(18669) rat ... Atp1a1(24211)
|
|
|
|
|
D8555
|
|
N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide
|
High affinity ligand for glial mitochondrial benzodiazepine receptors; stimulates neurosteroid biosynthesis; does not bind GABAA receptors
|
human ... BZRAP1(9256) rat ... Tspo(24230)
|
|
|
|
|
37281
|
|
2,3-Dihydrobenzofuran purum, ≥97.0% (GC)
|
|
human ... CYP1A2(1544)
|
|
|
|
|
183962
|
|
2,3-Dihydrobenzofuran 99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
M1022
|
|
Dihydrocapsaicin from Capsicum sp., ~90%
|
VR1 vanilloid receptor agonist.
|
human ... TRPV1(7442) rat ... Trpv4(66026)
|
|
|
|
|
37274
|
|
Dihydrocapsaicin natural, ≥80% (HPLC)
|
VR1 vanilloid receptor agonist.
|
|
|
|
|
|
C7980
|
|
Dihydroceramide C2 ≥98% (TLC), solid
|
Inactive form of C2 ceramide; may be used as a negative control.
|
|
|
|
|
|
C8230
|
|
Dihydroceramide C6 solid
|
Inactive form of C6 ceramide for use as a negative control.
|
|
|
|
|
|
C8605
|
|
Dihydroceramide C8 98%, waxy solid
|
Inactive form of C8 ceramide for use as a negative control.
|
|
|
|
|
|
D1641
|
|
Dihydrocytochalasin B
|
Effect on cell motility and morphology similar to that of cytochalasin B; does not inhibit glucose transport.
|
|
|
|
|
|
D4321
|
|
Dihydroeponemycin ≥98% (HPLC)
|
Dihydroeponemycin is an active derivative of eponemycin an antitumor antibiotic isolated from Streptomyces hygroscopicus. Dihydroeponemycin labels the catalytic threonine residues of the immunoproteasome subunits LMP2 and LMP7 and the constitutive proteasome subunit X, while epoxomicin covalently modifies the N-terminal catalytic threonine residues of the constitutive proteasome (X and Z) and immunoproteasome (LMP7 and MECL1) subunits.
|
|
|
|
|
|
D2763
|
|
Dihydroergotamine methanesulfonate salt powder
|
Agonist at vascular serotonin receptors; partial agonist at α-adrenergic and dopamine D2 receptors; vasoconstrictor.
|
human ... DRD2(1813)
|
|
|
|
|
D7006
|
|
Dihydrofolic acid ≥90%
|
Folic acid (FA) and dihydrofolic acid (FAH2) are substrates of dihydrofolate reductase(s) which reduce them to tetrahydrofolate (THF), which in turn supports ‘one carbon’ transfer. Tetrahydrofolates are required for de novo synthesis of purines, thymidylic acid and various amino acids and for post-translational methylation (epigenetics).
|
human ... DHFRP1(573971) mouse ... Dhfr(13361)
|
|
|
|
|
D1064
|
|
Dihydrokainic acid ≥98% (HPLC), powder
|
Dihydrokainic acid is a selective inhibitor of the GLT-1 glutamate transporter. At higher concentrations, dihydrokainate is a weak inhibitor of AMPA/kainate glutamic acid receptors.
|
human ... SLC1A1(6505), SLC1A2(6506), SLC1A3(6507) rat ... Slc1a2(29482), Slc1a3(29483)
|
|
|
|
|
D0670
|
|
Dihydroouabain
|
Cardiac glycoside; an inhibitor of the sodium-potassium pump.
|
|
|
|
|
|
D3314
|
|
D-erythro-Dihydrosphingosine ≥98%
|
Biosynthetic precursor to sphingosine; inhibits protein kinase C.
|
|
|
|
|
|
D4681
|
|
L-threo-Dihydrosphingosine ≥95% (TLC)
|
Sphingosine kinase inhibitor; protein kinase C alpha (PKCα) -specific inhibitor; Sphingosine analog; potentiates the effect of doxorubicin (DOX) in tumor-bearing animals.
|
|
|
|
|
|
D6783
|
|
DL-Dihydrosphingosine ≥98%, synthetic
|
Biosynthetic precursor of sphingosine.
|
|
|
|
|
|
D6908
|
|
DL-erythro-Dihydrosphingosine ≥99%, synthetic
|
D-Isomer is the biosynthetic precursor of sphingosine; inhibits protein kinase C, phospholipase A2, and phospholipase D.
|
human ... PLD1(5337), PLD2(5338), PLD3(23646), PLD4(122618), PLD5(200150), PPP2CA(5515), PPP2CB(5516), PPP2CBP(5517), PPP2R1A(5518), PPP2R1B(5519), PPP2R2A(5520), PPP2R2B(5521), PPP2R2C(5522), PPP2R3A(5523), PRKCA(5578), PRKCB(5579), PRKCD(5580), PRKCE(5581), PRKCG(5582), PRKCH(5583), PRKCI(5584)
|
|
|
|
|
D7033
|
|
DL-threo-Dihydrosphingosine ≥98%
|
Sphingosine kinase inhibitor.
|
|
|
|
|
|
D3439
|
|
D-erythro-Dihydrosphingosine 1-phosphate ≥98% (TLC), waxy solid
|
Negative control for sphingosine-1-phosphate.
|
human ... S1PR1(1901), S1PR2(9294), S1PR3(1903), S1PR4(8698), S1PR5(53637)
|
|
|
|
|
126217
|
|
2,4-Dihydroxybenzophenone 99%
|
|
rat ... Ar(24208)
|
|
|
|
|
D110507
|
|
4,4′-Dihydroxybenzophenone 99%
|
|
rat ... Ar(24208)
|
|
|
|
|
37613
|
|
4,4′-Dihydroxybenzophenone technical, ≥95% (HPLC)
|
|
rat ... Ar(24208)
|
|
|
|
|
UC441
|
|
6´,-7´-Dihydroxybergamottin
|
CYP3A4 inhibitor.
|
|
|
|
|
|
168734
|
|
4,4′-Dihydroxybiphenyl 97%
|
|
human ... ESR1(2099), ESR2(2100), MMP3(4314)
|
|
|
|
|
D2667
|
|
2,5-Dihydroxycinnamic acid methyl ester ≥95%, crystalline
|
Inhibitor of EGF receptor-associated tyrosine kinase.
|
|
|
|
|
|
D5564
|
|
7,8-Dihydroxycoumarin ≥97%, solid
|
Inhibitor of protein kinases.
|
|
|
|
|
|
D9503
|
|
3,4-Dihydroxy-DL-phenylalanine
|
Immediate precursor of dopamine; product of tyrosine hydroxylase
|
human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816) mouse ... DRD1(13488), DRD2(13489), DRD3(13490), DRD4(13491), DRD5(13492) rat ... DRD1(24316), DRD2(24318), DRD3(29238), DRD4(25432), DRD5(25195)
|
|
|
|
|
D1444
|
|
6,2′-Dihydroxyflavone ≥98% (HPLC), powder
|
6,2′-Dihydroxyflavone is a partial inverse agonist at GABAA receptors with α-subunit selectivity.
|
|
|
|
|
|
D5446
|
|
7,8-Dihydroxyflavone hydrate ≥98% (HPLC)
|
7,8-Dihydroxyflavone is a selective tyrosine kinase receptor B (TrkB) receptor agonist. It manifests all the therapeutic effects of brain-derived neurotrophic factor (BDNF)—such as protecting neurons from apoptosis, inhibiting kainic acid-induced toxicity, decreasing infarct volumes in stroke, and neuroprotecting in an animal model of Parkinson′s disease—without the poor pharmacokinetic profile of BDNF limiting its therapeutic potential.1
|
|
|
|
|
|
229075
|
|
1,8-Dihydroxy-3-methylanthraquinone 98%
|
Anticancer activity for chrysophanic acid is via the EGFR/mTOR mediated signaling transduction pathway 1. Chrysophanic acid has two hydrophobic positions on the molecule (C-6 and the methyl group attached to C-3) which are responsible for the compound′s activity against poliovirus 2.
|
human ... ELA2(1991)
|
|
|
|
|
37760
|
|
2,3-Dihydroxynaphthalene ≥98.0% (HPLC), purified by sublimation
|
|
human ... BAD(572)
|
|
|
|
|
37761
|
|
2,3-Dihydroxynaphthalene technical, ≥90% (HPLC)
|
|
human ... BAD(572)
|
|
|
|
|
850217
|
|
3,4-Dihydroxyphenylacetic acid 98%
|
|
|
|
|
|
|
D9378
|
|
3,4-Dihydroxy-D-phenylalanine powder, ≥98%
|
DOPA enantiomer that lacks biological activity.
|
|
|
|
|
|
D9628
|
|
3,4-Dihydroxy-L-phenylalanine ≥98% (TLC)
|
Natural isomer of the immediate precursor of dopamine; product of tyrosine hydroxylase
|
human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816) mouse ... DRD1(13488), DRD2(13489), DRD3(13490), DRD4(13491), DRD5(13492) rat ... DRD1(24316), DRD2(24318), DRD3(29238), DRD4(25432), DRD5(25195)
|
|
|
|
|
D1507
|
|
L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride solid
|
Precursor to L-DOPA that crosses the blood-brain barrier; antiparkinsonian agent.
|
|
|
|
|
|
D3689
|
|
(S)-3,5-Dihydroxyphenylglycine hydrate ≥98% (HPLC), powder
|
(S)-3,5-Dihydroxyphenylglycine hydrate is a group I metabotropic glutamate receptor agonist.
|
human ... GRM1(2911)
|
|
|
|
|
D2384
|
|
DL-3,4-Dihydroxyphenylserine ≥98% (HPLC), powder
|
Amino acid precursor of noradrenaline (NA); elevates brain NA concentrations.
|
|
|
|
|
|
P2016
|
|
3α,21-Dihydroxy-5α-pregnan-20-one ≥95%
|
Positive allosteric modulator of GABAA receptors.
|
human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562) rat ... Gabra2(29706)
|
|
|
|
|
P6285
|
|
17α,20β-Dihydroxy-4-pregnen-3-one crystalline
|
17α,20β-Dihydroxy-4-pregnen-3-one, also known as maturation-inducing steroid (MIS), is the most potent steroid for inducing final oocyte maturation in several species of fish.
|
|
|
|
|
|
144789
|
|
2,3-Dihydroxyquinoxaline 98%
|
|
rat ... Gria1(50592), Grik1(29559), Grin2a(24409)
|
|
|
|
|
D1530
|
|
1α,25-Dihydroxyvitamin D3 ≥99% (HPLC)
|
Biologically active form of vitamin D3 in calcium absorption and deposition. 1α,25-Dihydroxyvitamin D3 has widespread effects on cellular differentiation and proliferation, and can modulate immune responsiveness, and central nervous system function. Recent studies suggest that 1α,25-dihydroxyvitamin D3 acts as a chemopreventive agent against several malignancies including cancers of the prostate and colon and shows synergy with other anticancer compounds. Cholecalciferol is an inactive form of vitamin D3 which undergoes various levels of hydroxylation to form active vitamin D3 analogs. 1α-Hydroxyvitamin D3 (alfacalcidol is a synthetic analog that is metabolized to 1,25-dihydroxycholecalciferol, the biologically active form of vitamin D3 in calcium absorption and deposition. 1α,25-Dihydroxyvitamin D3 has widespread effects on cellular differentiation and proliferation, and can modulate immune responsiveness, and central nervous system function. Recent studies suggest that 1α,25-dihydroxyvitamin D3 acts as a chemopreventive agent against several malignancies including cancers of the prostate and colon and shows synergy with other anticancer compounds.
|
human ... VDR(7421)
|
|
|
|
|
17936
|
|
1α,25-Dihydroxyvitamin D3 ≥97.0% (HPLC)
|
Biologically active form of vitamin D3 in calcium absorption and deposition. 1α,25-Dihydroxyvitamin D3 has widespread effects on cellular differentiation and proliferation, and can modulate immune responsiveness, and central nervous system function. Recent studies suggest that 1α,25-dihydroxyvitamin D3 acts as a chemopreventive agent against several malignancies including cancers of the prostate and colon and shows synergy with other anticancer compounds.
|
human ... VDR(7421)
|
|
|
|
|
113263
|
|
1,3-Diisopropylbenzene 96%
|
|
human ... GABRA1(2554)
|
|
|
|
|
D125407
|
|
N,N′-Diisopropylcarbodiimide 99%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
38370
|
|
N,N′-Diisopropylcarbodiimide purum, ≥98.0% (GC)
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
685666
|
|
N,N′-Diisopropylcarbodiimide, ChemDose™ tablets Loading: 0.15mmol per tablet
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D125601
|
|
3,5-Diisopropylcatechol technical grade, 90%
|
|
human ... GABRA1(2554)
|
|
|
|
|
D0879
|
|
Diisopropylfluorophosphate
|
Potent inhibitor of serine proteases such as trypsin and chymotrypsin, and of acetylcholinesterase; also inhibits cathepsin G, cholinesterase, coagulation factor Xa, leucocyte elastase, pancreatic elastase, tissue kallikrein, plasmin, subtilisin, and thrombin. Inhibition of acetylcholinesterase makes this compound especially toxic. Inhibits apoptosis induced by ricin and bacterial toxins.
|
human ... PTGS1(5742), PTGS2(5743)
|
|
|
|
|
D126608
|
|
2,6-Diisopropylphenol 97%
|
|
human ... CYP1A2(1544), GABRA1(2554) rat ... Gabra2(29706)
|
|
|
|
|
376930
|
|
2,6-Diisopropylphenyl isocyanate 98%
|
|
human ... GABRA1(2554)
|
|
|
|
|
308218
|
|
2,6-Diisopropylphenyl isocyanate technical grade, 90%
|
|
human ... GABRA1(2554)
|
|
|
|
|
D126802
|
|
1,3-Diisopropyl-2-thiourea 99%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D4565
|
|
2,3-Di-nor-8-isoprostaglandin F2α ≥98%, methyl acetate solution
|
|
|
|
|
|
|
D5294
|
|
Dilazep dihydrochloride powder
|
Adenosine uptake inhibitor; coronary and cerebral vasodilator; suppresses effects of ischemia; antiplatelet agent.
|
human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140)
|
|
|
|
|
D2521
|
|
(+)-cis-Diltiazem hydrochloride ≥99% (HPLC)
|
Blocks slow, or L-type Ca2+ channels; regulates Ca2+ release from intracellular stores in neutrophils; stimulates 1,4-dihydropyridine binding to Ca2+ channels; coronary vasodilator.
|
|
|
|
|
|
GLDIL
|
|
Diluent A For general membrane labeling
|
|
|
|
|
|
|
CGLDIL
|
|
Diluent C for General Membrane Labeling
|
|
|
|
|
|
|
D6196
|
|
Dimebon dihydrochloride hydrate ≥98% (HPLC)
|
Mechanism of neuroprotection and cognition enhancement is not certain, but Dimebon blocks both cholinesterase and the NMDA receptor simultaneously and also appears to block the action of neurotoxic β-amyloid proteins and inhibit L-type calcium channels, and may exert a neuroprotective effect by blocking a novel target that involves mitochondrial pores.
|
|
|
|
|
|
381802
|
|
3,3′-Dimethoxybenzil 99%
|
|
human ... ACHE(43), BCHE(590), CES1(1066)
|
|
|
|
|
159611
|
|
4,4′-Dimethoxybenzil 98%
|
|
human ... ACHE(43), BCHE(590), CES1(1066)
|
|
|
|
|
A88409
|
|
4,4′-Dimethoxybenzoin 95%
|
|
human ... ACHE(43), BCHE(590), CES1(1066)
|
|
|
|
|
D5943
|
|
2-(3,4-Dimethoxy-benzoylamino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amide ≥98% (HPLC), solid
|
Flt-3 (fms-related tyrosine kinase 3) inhibitor
|
|
|
|
|
|
254886
|
|
6,7-Dimethoxycoumarin 98%
|
|
mouse ... Maoa(17161) rat ... Aldh1a2(116676)
|
|
|
|
|
D6571
|
|
3′,4′-Dimethoxyflavone
|
3′,4′-dimethoxyflavone is a competitive antagonist of the AhR that inhibits AhR-mediated induction of CYP1A1, and also displays antiestrogen activity in breast tumor cell lines. The compound blocks transformation of the cytosolic AhR complex, and formation of nuclear AhR complexes.
|
|
|
|
|
|
357677
|
|
2,5-Dimethoxyphenethylamine 97%
|
|
rat ... Htr2a(29595), Htr2c(25187)
|
|
|
|
|
D135550
|
|
2,6-Dimethoxyphenol 99%
|
|
human ... GABRA1(2554)
|
|
|
|
|
W313718
|
|
2,6-Dimethoxyphenol ≥98%, FG
|
|
human ... GABRA1(2554)
|
|
|
|
|
196118
|
|
2,2-Dimethoxy-2-phenylacetophenone 99%
|
|
human ... ACHE(43), BCHE(590), CES1(1066)
|
|
|
|
|
D114
|
|
(±)-1-(2,5-Dimethoxyphenyl)-2-aminopropane hydrochloride
|
|
human ... SLC9A1(6548) rat ... Slc9a1(24782), Slc9a2(24783), Slc9a3(24784)
|
|
|
|
|
D6068
|
|
N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride ≥98% (HPLC), solid
|
Aurora Kinase Inhibitor
|
|
|
|
|
|
38827
|
|
4,4′-Dimethoxytriphenylmethyl chloride ≥97.0% (HPLC)
|
|
human ... HTR2A(3356), HTR2B(3357), HTR2C(3358) rat ... Htr1a(24473), Htr2a(29595)
|
|
|
|
|
A4562
|
|
5-(N,N-Dimethyl)amiloride hydrochloride
|
Selective blocker of Na+/H+ antiport; IC50 = 6.9 μM.
|
human ... SCNN1A(6337), SCNN1B(6338), SCNN1D(6339), SCNN1G(6340), SLC9A1(6548) mouse ... Scnn1a(20276), Scnn1b(20277), Scnn1d(140501), Scnn1g(20278) rat ... Scnn1a(25122), Scnn1b(24767), Scnn1g(24768), Slc9a1(24782), Slc9a2(24783), Slc9a3(24784)
|
|
|
|
|
298573
|
|
4-Dimethylamino-2,2,6,6-tetramethylpiperidine 96%
|
|
rat ... Grin2a(24409)
|
|
|
|
|
D4268
|
|
NG,NG-Dimethylarginine dihydrochloride
|
Reversible inhibitor of nitric oxide synthetase in vivo and in vitro.
|
human ... NOS1(4842), NOS2(4843), NOS2B(201288), NOS2C(645740), NOS3(4846)
|
|
|
|
|
306940
|
|
2,6-Dimethylbenzenethiol 95%
|
|
human ... GABRA1(2554)
|
|
|
|
|
W366609
|
|
2,6-Dimethylbenzenethiol ≥95%
|
|
human ... GABRA1(2554)
|
|
|
|
|
146706
|
|
4,4′-Dimethylbenzil 97%
|
|
human ... ACHE(43), BCHE(590), CES1(1066)
|
|
|
|
|
D8008
|
|
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid ≥95%
|
Inhibitor of phospholipase A2 and lipoxygenase.1 Inhibits endogenous synthesis of leukotrienes.
|
human ... ADORA2A(135), ADORA2B(136)
|
|
|
|
|
36943
|
|
1,2-Dimethylnaphthalene analytical standard, for environmental analysis
|
|
human ... CYP1A2(1544)
|
|
|
|
|
360740
|
|
1,2-Dimethylnaphthalene 95%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
D170208
|
|
1,3-Dimethylnaphthalene 96%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
37883
|
|
1,4-Dimethylnaphthalene analytical standard, for environmental analysis
|
|
human ... CYP1A2(1544)
|
|
|
|
|
D170305
|
|
1,4-Dimethylnaphthalene 95%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
45785
|
|
1,6-Dimethylnaphthalene analytical standard, for environmental analysis
|
|
human ... CYP1A2(1544)
|
|
|
|
|
250937
|
|
1,6-Dimethylnaphthalene 99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
409901
|
|
1,7-Dimethylnaphthalene 99%
|
|
human ... CYP1A2(1544), CYP2A6(1548) mouse ... Cyp2a5(13087)
|
|
|
|
|
126535
|
|
2,6-Dimethylnaphthalene 99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
279919
|
|
2,7-Dimethylnaphthalene 99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
36715
|
|
2,6-Dimethylphenol PESTANAL®, analytical standard
|
|
human ... GABRA1(2554)
|
|
|
|
|
D174904
|
|
2,6-Dimethylphenol ≥99.5%
|
|
human ... GABRA1(2554)
|
|
|
|
|
D175005
|
|
2,6-Dimethylphenol 99%
|
|
human ... GABRA1(2554)
|
|
|
|
|
442328
|
|
2,6-Dimethylphenol analytical standard
|
|
human ... GABRA1(2554)
|
|
|
|
|
522449
|
|
α,4-Dimethylphenylacetic acid 97%
|
|
human ... IL8RA(3577)
|
|
|
|
|
D5891
|
|
1,1-Dimethyl-4-phenylpiperazinium iodide ≥98% (TLC or titration), powder
|
Nicotinic acetylcholine receptor agonist.
|
human ... CHRNA1(1134), CHRNA10(57053), CHRNA2(1135), CHRNA3(1136), CHRNA4(1137), CHRNA5(1138), CHRNA6(8973), CHRNA7(1139), CHRNA9(55584), CHRNB1(1140), CHRNB2(1141), CHRNB3(1142), CHRNB4(1143) rat ... Chrna2(170945), Chrna3(25101), Chrna4(25590), Chrnb2(54239), Chrnb4(25103)
|
|
|
|
|
P2278
|
|
1,3-Dimethyl-8-phenylxanthine crystalline
|
Selective A1 adenosine receptor antagonist.
|
human ... ADORA1(134), ADORA2B(136), ADORA3(140) rat ... Adora1(29290), Adora2a(25369), Adora2b(29316)
|
|
|
|
|
346438
|
|
9-[3-(cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride monohydrate 97%
|
Cocaine antagonist
|
human ... DRD3(1814) rat ... Slc6a2(20538), Slc6a3(24898), Slc6a4(25553)
|
|
|
|
|
308110
|
|
N,N′-Dimethyl-1,3-propanediamine 97%
|
|
rat ... Grin2a(24409)
|
|
|
|
|
226920
|
|
2,2-Dimethyl-1,3-propanediamine 99%
|
|
rat ... Grin2a(24409)
|
|
|
|
|
D134
|
|
3,7-Dimethyl-1-propargylxanthine ≥98% (HPLC), solid
|
Selective A2 adenosine receptor antagonist.
|
human ... ADORA2A(135), ADORA2B(136) rat ... Adora1(29290), Adora2a(25369)
|
|
|
|
|
D0160
|
|
16,16-Dimethylprostaglandin E2 methyl acetate solution
|
|
|
|
|
|
|
370207
|
|
4,6-Dimethyl-α-pyrone 99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
D5766
|
|
5,5-Dimethyl-1-pyrroline N-oxide ≥97%
|
|
|
|
|
|
|
144029
|
|
2,6-Dimethylquinoline 98%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
179523
|
|
Dimethyl suberimidate dihydrochloride 98%
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
74835
|
|
Dimethyl suberimidate dihydrochloride ≥98.0% (AT)
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
274380
|
|
Dimethyl sulfide anhydrous, ≥99.0%
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
471577
|
|
Dimethyl sulfide ≥99%
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
W274623
|
|
Dimethyl sulfide natural, ≥99%, FCC, FG
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
41625
|
|
Dimethyl sulfide ≥95.0% (GC)
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
W274615
|
|
Dimethyl sulfide redistilled, ≥99%, FCC, FG
|
|
rat ... Maoa(29253), Maob(25750)
|
|
|
|
|
261394
|
|
1,1-Dimethylurea 99%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
36574
|
|
N,N′-Dimethylurea PESTANAL®, analytical standard
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
40410
|
|
N,N′-Dimethylurea (sym.), ≥95.0% (HPLC), technical
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D5385
|
|
1,7-Dimethylxanthine ~98%, solid
|
Adenosine receptor ligand; major metabolite of caffeine
|
human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140) rat ... Adora1(29290), Adora2a(25369)
|
|
|
|
|
41763
|
|
3,9-Dimethylxanthine ≥99.0%
|
|
rat ... Adora1(29290), Adora2a(25369)
|
|
|
|
|
SML0079
|
|
DiMNF ≥98% (HPLC)
|
DiMNF is a naphthoflavone derivative, selective aryl hydrocarbon receptor modulator (SAhRM). DiMNF is an AHR ligand that does not induce the expression of AHR dependent genes, such as CYP1A1, but inhibits the expression of cytokine-induced acute phase response proteins such as serum amyloid A and complement C3.
|
|
|
|
|
|
P2663
|
|
1,2-Dimyristoyl-sn-glycero-3-phosphocholine ≥99%
|
|
|
|
|
|
|
D131
|
|
3,5-Dinitrocatechol solid
|
Selective inhibitor of catechol O-methyl transferase (COMT); penetrates the blood brain barrier and is useful both orally and parenteraly in experiments where inhibition of COMT in the central nervous system is required.
|
human ... COMT(1312)
|
|
|
|
|
D129
|
|
R-(+)-DIOA ≥98% (HPLC), solid
|
Potent [K+,Cl-]-cotransport inhibitor that shows no side effects on the bumetanimide-sensitive [Na+,K+,Cl-]-cotransport system.
|
|
|
|
|
|
P3591
|
|
1,2-Dioctanoyl-sn-glycerol 3-phosphate sodium salt ≥99%
|
|
|
|
|
|
|
D1634
|
|
Diosgenin ≥93%
|
Diosgenin is a plant steroid which induces apoptosis in colon cancer cell lines and induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells.
|
human ... UGT1A4(54657)
|
|
|
|
|
P0763
|
|
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine semisynthetic, ≥99%
|
|
|
|
|
|
|
P4329
|
|
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine ≥99% (TLC)
|
|
|
|
|
|
|
P6990
|
|
1,2-Dipalmitoylphosphatidylinositol 3,4-diphosphate sodium salt ≥98%, solid
|
Diphosphorylated phosphatidylinositol that may be hydrolyzed by PI-specific phospholipase C to generate IP3 and DAG.
|
|
|
|
|
|
P7115
|
|
1,2-Dipalmitoylphosphatidylinositol 4,5-diphosphate triammonium salt ≥98%, solid
|
Diphosphorylated phosphatidylinositol that may be hydrolyzed by PI-specific phospholipase C to generate IP3 and DAG.
|
|
|
|
|
|
P4240
|
|
1,2-Dipalmitoylphosphatidylinositol 3,4,5-trisphosphate tetrasodium salt ≥98%
|
Proposed as signal transduction modulator.
|
|
|
|
|
|
D3630
|
|
Diphenhydramine hydrochloride ≥98% (TLC)
|
H1 histamine receptor antagonist
|
human ... HRH1(3269)
|
|
|
|
|
D7774
|
|
Diphenhydramine hydrochloride analytical standard
|
|
|
|
|
|
|
D6071
|
|
Diphenylacetohydroxamic acid ≥98% (HPLC)
|
Diphenylacetohydroxamic acid is a class IIa selective histone deacetylase inhibitor.
|
|
|
|
|
|
45456
|
|
Diphenylamine PESTANAL®, analytical standard
|
|
human ... UGT1A4(54657)
|
|
|
|
|
33149
|
|
Diphenylamine puriss. p.a., redox indicator, ACS reagent, reag. Ph. Eur., ≥98% (GC)
|
|
human ... UGT1A4(54657)
|
|
|
|
|
242586
|
|
Diphenylamine ACS reagent, ≥99%
|
|
human ... UGT1A4(54657)
|
|
|
|
|
112763
|
|
Diphenylamine ReagentPlus®, 99%
|
|
human ... UGT1A4(54657)
|
|
|
|
|
D206539
|
|
Diphenyl carbonate ReagentPlus®, 99%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
278971
|
|
Diphenyl N-cyanocarbonimidate 97%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D2926
|
|
Diphenyleneiodonium chloride ≥98%
|
A potent and reversible inhibitor of nitric oxide synthetase from macrophages and endothelial cells. Also inhibits other flavoenzymes such as neutrophil NADPH oxidase.
|
human ... NOS1(4842), NOS2(4843), NOS2B(201288), NOS2C(645740), NOS3(4846) mouse ... Pik3r1(18708)
|
|
|
|
|
240834
|
|
Diphenyl ether ReagentPlus®, ≥99%
|
|
human ... TTR(7276)
|
|
|
|
|
P24101
|
|
Diphenyl ether ReagentPlus®, 99%
|
|
human ... TTR(7276)
|
|
|
|
|
W366706
|
|
Diphenyl ether ≥99%
|
|
human ... TTR(7276)
|
|
|
|
|
D206709
|
|
2,2-Diphenylethylamine 96%
|
|
rat ... Htr2a(29595)
|
|
|
|
|
43029
|
|
1,3-Diphenylguanidine analytical standard (for titrimetry)
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850) rat ... Grin2a(24409), Scnn1g(24768)
|
|
|
|
|
D207756
|
|
1,3-Diphenylguanidine 97%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850) rat ... Grin2a(24409), Scnn1g(24768)
|
|
|
|
|
D4007
|
|
5,5-Diphenylhydantoin ≥99%
|
Reduces incidence of grand mal seizures; appears to stabilize excitable membranes perhaps through effects on Na+, K+, and Ca2+ channels.
|
human ... CNR1(1268), CNR2(1269), CYP2C9(1559) rat ... Faah(29347), Scn1a(81574), Scnn1g(24768), Slc6a1(79212)
|
|
|
|
|
D4505
|
|
5,5-Diphenylhydantoin sodium salt ≥99%
|
Reduces incidence of grand mal seizures; appears to stabilize excitable membranes perhaps through effects on Na+, K+, and Ca2+ channels.
|
human ... CNR1(1268), CNR2(1269), CYP2C9(1559) rat ... Faah(29347), Scn1a(81574), Scnn1g(24768), Slc6a1(79212)
|
|
|
|
|
D33454
|
|
1,3-Diphenyl-1,3-propanedione 98%
|
|
human ... ACHE(43), BCHE(590), CES1(1066)
|
|
|
|
|
33790
|
|
1,3-Diphenyl-2-propanone purum, ≥98.0% (GC)
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
W239704
|
|
1,3-Diphenyl-2-propanone ≥98%, FG
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D204609
|
|
1,3-Diphenyl-2-propanone ≥99%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
11970
|
|
1,3-Diphenyl-2-propenone ≥98.0% (GC)
|
|
rat ... Ar(24208)
|
|
|
|
|
D8816
|
|
N-(3,3-Diphenylpropyl)glycinamide >98% (HPLC), solid
|
NMDA glutamate receptor open channel blocker.
|
human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRINA(2907)
|
|
|
|
|
D213209
|
|
Diphenyl-4-pyridylmethane 99%
|
|
rat ... Slc6a3(24898), Slc6a4(25553)
|
|
|
|
|
D214256
|
|
5,5-Diphenyl-2-thiohydantoin 99%
|
|
human ... CNR1(1268), CNR2(1269) rat ... Faah(29347)
|
|
|
|
|
T28355
|
|
N,N′-Diphenylthiourea 98%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
142158
|
|
1,3-Diphenylurea 98%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D0564
|
|
Diphtheria Toxin from Corynebacterium diphtheriae lyophilized powder
|
Inhibits protein synthesis by catalyzing ADP-ribosylation of eukaryotic aminoacyltransferase II.
|
|
|
|
|
|
D2189
|
|
[Glu52]-Diphtheria toxin from Corynebacterium diphtheriae lyophilized powder
|
|
|
|
|
|
|
D132
|
|
N,N-Dipropyl-5-carboxamidotryptamine maleate salt solid
|
Potent and selective 5-HT1A serotonin receptor agonist.
|
human ... HTR1A(3350)
|
|
|
|
|
D108
|
|
1,3-Dipropyl-7-methylxanthine solid
|
Caffeine analog with some selectivity for A2 adenosine receptors.
|
human ... ADORA2A(135), ADORA2B(136) rat ... Adora1(29290), Adora2a(25369)
|
|
|
|
|
A022
|
|
1,3-Dipropyl-8-(p-sulfophenyl)xanthine powder
|
Water soluble adenosine receptor antagonist with slight selectivity for A1 receptors.
|
human ... ADORA1(134), ADORA2B(136), ADORA3(140) rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
|
|
|
|
|
43567
|
|
N,N′-Dipropylurea purum, ≥97.0% (C)
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
417629
|
|
N,N′-Dipropylurea 97%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D9766
|
|
Dipyridamole ≥98% (TLC), powder
|
Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.
|
human ... CYP1A2(1544), PDE10A(10846), PDE5A(8654), SLC29A1(2030) mouse ... Slc29a1(63959)
|
|
|
|
|
127221
|
|
Di(2-pyridyl) ketone 99%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D7689
|
|
Diquine ≥98%, solid
|
A nicotinic cholinoreceptor antagonist at the neuromuscular junction; curare-like ganglioblocker.
|
|
|
|
|
|
G0776
|
|
Disialoganglioside-GD2 from bovine brain ~95%, lyophilized powder, semisynthetic
|
Cell surface component from disialoganglioside-GD1b.
|
|
|
|
|
|
G2392
|
|
Disialoganglioside GD1a from bovine brain ≥95% (TLC), lyophilized powder
|
The major ganglioside in brain. Converted to GM1 by bacterial and mammalian sialidase. Differentiation marker for cell growth.
|
|
|
|
|
|
G8146
|
|
Disialoganglioside GD1b from bovine brain ~95%, lyophilized powder
|
May act as a bacterial toxin receptor (tetanus, botulinus); high levels found in gliomas and astrocytomas.
|
|
|
|
|
|
D7644
|
|
Disopyramide
|
Class IA antiarrhythmic; sodium channel blocker
|
human ... CYP1A2(1544), KCNH1(3756), SCN5A(6331)
|
|
|
|
|
D6035
|
|
Disopyramide phosphate salt
|
Class IA antiarrhythmic; sodium channel blocker
|
|
|
|
|
|
P1138
|
|
1,2-Distearoyl-sn-glycero-3-phosphocholine ≥99%
|
|
|
|
|
|
|
P6517
|
|
1,2-Distearoyl-sn-glycero-3-phosphocholine ≥99% (TLC)
|
|
|
|
|
|
|
43698
|
|
1,2-Distearoyl-sn-glycero-3-phosphocholine ≥99.0% (TLC)
|
|
|
|
|
|
|
D2773
|
|
Dithranol ≥90% (HPLC)
|
|
mouse ... Alox12(11684)
|
|
|
|
|
10608
|
|
Dithranol matrix substance for MALDI-MS, ≥98.0%
|
|
mouse ... Alox12(11684)
|
|
|
|
|
207713
|
|
1,3-Di-o-tolylguanidine 99%
|
|
human ... EBP(10682)
|
|
|
|
|
147109
|
|
1,3-Di-o-tolyl-2-thiourea 97%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
131091
|
|
1,3-Di-p-tolyl-2-thiourea 97%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
D2425
|
|
Diuron ≥98%
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
45463
|
|
Diuron PESTANAL®, analytical standard
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
45851
|
|
Diuron solution 100 ng/μL in acetonitrile, PESTANAL®, analytical standard
|
|
human ... EPHX2(2053) mouse ... Ephx2(13850)
|
|
|
|
|
V3700
|
|
Divinyl sulfone contains <650 ppm hydroquinone as inhibitor, 97%
|
|
human ... LOC129293(129293)
|
|
|
|
|
D5689
|
|
DM 235 solid
|
Potent nootropic agent.
|
|
|
|
|
|
D6317
|
|
DMeOB ≥98% (HPLC), solid
|
Negative allosteric modulator at the metabotropic glutamate receptor mGluR5.
|
|
|
|
|
|
D5817
|
|
DMXAA ≥98% (HPLC), solid
|
DMXAA is an apoptosis inducer; anti-vascular.
|
|
|
|
|
|
D0540
|
|
DNQX ≥98% (TLC)
|
A competitive kainate, quisqualate (non-NMDA) glutamate receptor antagonist.
|
human ... GRIA1(2890), GRIA2(2891), GRIK1(2897), GRIK2(2898), GRIK3(2899), GRIK4(2900), GRIK5(2901) mouse ... Gria1(14799) rat ... Gria1(50592), Grik1(29559), Grik4(24406), Grin2a(24409)
|
|
|
|
|
D0676
|
|
Dobutamine hydrochloride ≥98%
|
β1-Adrenoceptor receptor agonist.
|
human ... ADRB1(153)
|
|
|
|
|
W240001
|
|
γ-Dodecalactone ≥97%, FCC, FG
|
|
human ... CYP1A2(1544)
|
|
|
|
|
286486
|
|
Dodecanoic anhydride 98%
|
|
human ... FNTA(2339), PGGT1B(5229)
|
|
|
|
|
372102
|
|
4-Dodecylphenol, mixture of isomers
|
|
rat ... Ar(24208)
|
|
|
|
|
PZ0016
|
|
Dofetilide ≥98% (HPLC)
|
Dofetilide is a Class III antiarrhythmic and hERG channel blocker. Dofetilide selectively blocks the rapid component of the delayed rectifier outward potassium current (IKr).
|
|
|
|
|
|
D153
|
|
(R)(−)-DOI hydrochloride ≥98% (HPLC), solid
|
Potent and selective 5-HT2 serotonin receptor agonist that crosses the blood-brain barrier; more potent enantiomer of ±-DOI hydrochloride.
|
human ... HTR2A(3356), HTR2B(3357), HTR2C(3358)
|
|
|
|
|
D101
|
|
(±)-DOI hydrochloride ≥98% (HPLC), solid
|
(±)-DOI hydrochloride is a potent and selective 5-HT2 serotonin receptor agonist that crosses the blood-brain barrier, increases dopamine turnover and the treatment with DOI counteracted the expression of the nicotine-induced locomotor and neurochemical sensitization, but had no effect on nicotine-induced behavioral disinhibition. The responses to DOI provide evidence that of these receptors are abundant in the cortex, and show relatively lower levels in hippocampus and cerebellum.
|
human ... HTR2A(3356), HTR2B(3357), HTR2C(3358)
|
|
|
|
|
D5566
|
|
Dolastatin 15 ≥95%
|
|
|
|
|
|
|
D6152
|
|
Domoic acid ≥90% (HPLC)
|
Potent agonist at receptors for excitatory amino acids glutamate and kainate; has highest affinity for AMPA/kainate receptor of any kainate agonist; causes excessive excitation of neurons leading to depletion of energy stores.
|
human ... GRIK1(2897)
|
|
|
|
|
D122
|
|
Domperidone powder, ≥98% (HPLC)
|
Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.
|
human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816), KCNH2(3757) rat ... Drd1a(24316), Drd2(24318), Drd3(29238), Htr3a(79246)
|
|
|
|
|
D6821
|
|
Donepezil hydrochloride monohydrate ≥98% (HPLC)
|
Donepezil monohydrochloride monohydrate is a centrally acting reversible acetylcholinesterase inhibitor.
|
|
|
|
|
|
D6446
|
|
DOV 216,303 ≥98% (HPLC)
|
Triple reuptake inhibitor (TRI); serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI); IC50 values of ~20, 14, and 78 nM, respectively.
|
|
|
|
|
|
D9815
|
|
Doxazosin mesylate ≥97% (HPLC), powder
|
α1-adrenoceptor antagonist; relaxes smooth muscles of the prostate
|
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146) rat ... Adra1a(29412), Adra1b(24173), Adra1d(29413)
|
|
|
|
|
D4526
|
|
Doxepin hydrochloride ~85% E-isomer basis, ≥98% (GC), 15% Z-isomer basis, powder
|
Tricyclic antidepressant that is a more potent inhibitor of norepinephrine uptake than of serotonin uptake; antagonist at H1 histamine, muscarinic cholinergic, and α-adrenoreceptors.
|
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133), HRH1(3269), HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)
|
|
|
|
|
D1515
|
|
Doxorubicin hydrochloride 98.0-102.0% (HPLC)
|
Antitumour antibiotic. Effect of adriamycin® on heart mitochondrial DNA;1 Properties.2,3 Inhibitor of reverse transcriptase and RNA polymerase; immunosuppressive agent; intercalates in DNA. Naturally fluorescent anthracycline antibiotic, anticancer drug. Doxorubicin is a substrate of MRP1 which was first cloned from a DOX-resistant lung cancer cell line. Fluorescent property has been exploited for the measurement of drug efflux pump activities as well as resolving the important question of intracellular localization of various multidrug resistance proteins and the role of subcellular organelles (Golgi and lysosome) in the sequestration of drugs and its implication in drug resistant phenotypes.
|
|
|
|
|
|
D9891
|
|
Doxycycline hyclate ≥98% (TLC)
|
Derivative of oxytetracycline. A broad spectrum inhibitor used to inhibit matrix metallo-proteinases (MMP) such as type 1 collagenase in studies on would healing and tissue remodeling. Doxycycline hyclate inhibits the inflammatory response to the Lyme Disease Spirochete Borrelia burgdorferi3. It is a broad spectrum inhibitor of matrix metalloproteinases in vivo.
|
|
|
|
|
|
D3775
|
|
Doxylamine succinate salt
|
H1 histamine receptor antagonist; hypnotic.
|
human ... HRH1(3269)
|
|
|
|
|
SML0186
|
|
Dp44mT ≥98% (HPLC)
|
Dp44mT is an iron chelator that works as a selective anticancer agent. As other iron chelators it can serve as a therapeutic adjunct to doxorubicin treatment. Additionally Dm44mT possess DNA-damaging activity. It appears that that activity is mediated by top2a inhibition.
|
|
|
|
|
|
SML0202
|
|
DPH ≥98% (HPLC)
|
DPH is a potent cell permeable c-Abl activator. DPH binds to the myristoyl binding site and leads to activation of c-Abl kinase activity. The compound stimulates the phosphorylation of c-Abl and its downstream substrate Crk.
|
|
|
|
|
|
D7443
|
|
DPO-1 needles, >97% (NMR)
|
DPO-1 is an inhibitor of human Kv1.5 potassium channel; representative blocker of a novel pharmacophore. The Kv1.5 potassium channel, which underlies the ultrarapid delayed rectifier current, IKur, is reported to be enriched in human atrium versus ventricle, and has been proposed as a target for novel atrial antiarrhythmic therapy. The administration of the IKur blocker (2-isopropyl-5-methyl-cyclohexyl) diphenylphosphine oxide (DPO-1) increases myocardial refractoriness in both atrium and ventricle of rat, but produces an atrial-selective increase in refractoriness in primates; appears to be 15-fold more selective for Kv1.5 vs Kv3.1 channels expressed in Xenopus oocytes. IC50 = 0.16-0.76 μM at 0.1 Hz pulsing frequency; Kd = 0.6 μM.
|
|
|
|
|
|
D4071
|
|
5, 15-DPP
|
5, 15-DPP is a selective STAT3 inhibitor and a selective STAT3-SH2 antagonist
|
|
|
|
|
|
D7821
|
|
dPPA ≥98% (HPLC)
|
Selective activator of PKC beta dPPA is a phorbol ester that selectively activates the beta isotype of PKC. It is approximately 100-fold more potent for PKC-beta than the alpha, gamma or delta isotypes. PKC family members each have specific functions, but PKC-beta and delta appear to share similar expression profiles, and both are involved in regulating apoptosis and B cell activation, thus dPPA is a useful tool in determining PKCbeta specific signaling events.
|
|
|
|
|
|
D2571
|
|
DPPE hydrochloride ≥98% (HPLC)
|
DPPE is a potent, selective ligand of the microsomal anti-estrogen binding site. DPPE is a tamoxifen derivataive that binds with high affinity to the anti-estrogen binding site, but unlike tamoxifen, does not bind to the estrogen receptor. DPPE sensitizes MDR tumor cells to chemotherapy and also inhibits histamine binding at the intracellular histamine site.
|
|
|
|
|
|
D5314
|
|
DPQ ≥98% (HPLC), solid
|
DPQ is a very potent poly(ADP-ribose) polymerase (PARP) inhibitor.
|
|
|
|
|
|
D6946
|
|
(R)-DRF053 hydrochloride hydrate ≥98% (HPLC)
|
DRF053 is a more potent version of roscovitine. It is 2 fold more potent against CDK5 (80 nM) and over 150 times more potent against CDK1 (14 nM).
|
|
|
|
|
|
D1414
|
|
Droperidol
|
D1, D2 dopamine receptor antagonist; butyrophenone antipsychotic and anti-emetic.
|
human ... DRD1(1812), DRD2(1813), KCNH1(3756), KCNH2(3757)
|
|
|
|
|
SML0147
|
|
Drospirenone ≥98% (HPLC)
|
Drospirenone is a fourth-generation progestin that has antimineralocorticoid, and antiandrogenic activity in addition to potent progestogenic activity. In two recent studies drospirenone appeared to double the risk of venous thromboembolism compared to levonorgestrel, although other studies found little added risk.
|
|
|
|
|
|
D6321
|
|
Droxinostat ≥98% (HPLC)
|
Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8.
|
|
|
|
|
|
D206
|
|
S(−)-DS 121 hydrochloride solid
|
Dopamine autoreceptor antagonist with some selectivity for the D3 dopamine receptor.
|
human ... DRD3(1814)
|
|
|
|
|
D5821
|
|
DS2 ≥98% (HPLC)
|
DS2 is a selective positive allosteric modulator of δ-GABAA receptors.
|
|
|
|
|
|
D0444
|
|
DT-2 trifluoroacetate salt ≥95% (HPLC), film
|
Cell permeable cGMP protein kinase (PKG) inhibitor
|
|
|
|
|
|
D3946
|
|
DY 131 ≥98% (HPLC)
|
DY 131 is an estrogen related receptor ERRβ and ERRy agonist with minimal activity at ERRα, ERα and ERβ
|
|
|
|
|
|
D7693
|
|
Dynasore hydrate
|
Dynasore is a cell-permeable, reversible noncompetitive dynamin 1 and dynamin 2 GTPase activity inhibitor.
|
|
|
|
|
|
D8147
|
|
Dynorphin A porcine ≥95% (HPLC)
|
Endogenous κ-agonist that is resistant to enzymatic degradation.
|
human ... OPRK1(4986) mouse ... Oprd1(18386) pig ... PDYN(445529) rat ... Oprd1(24613)
|
|
|
|
|
SRP3025
|
|
sDLL-1 human recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE), ≥95% (HPLC), cell culture tested
|
Human sDLL-1 comprises the extracellular signaling domain of DLL-1, a member of a structurally-related family of single-pass type I trans-membrane proteins that serve as ligands for Notch receptors. It is expressed in the heart and pancreas, and to a lesser extent in various other tissues. Recombinant human sDLL-1 is a 57.0-60.0 kDa glycoprotein containing 522 amino-acid residues
|
human ... DLL1(28514)
|
|
|
|
|
SRP3026
|
|
sDLL-4 human recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE), ≥95% (HPLC), cell culture tested
|
Human sDLL4 comprises the extracellular signaling domain of DLL, a member of a structurally-related family of single-pass type I trans-membrane proteins that serve as ligands for Notch receptors. Recombinant human sDLL4 is a 54.0 kDa glycoprotein containing 498 amino-acid residues.
|
human ... DLL4(54567)
|
|
|
|